Investing
The company will use the funds to develop new products, expand its operations and acquire other companies.
The funding boosts the Australia-based company's valuation to $465 million and brings its total raise to almost $100 million.
The company will use the funds to develop AI capabilities and move into weight loss, cardiometabolic care, diabetes, thyroid disorders and cardiovascular disease.
Also, JLK has received its seventh regulatory clearance from Japan for its stroke AI.
The company's platform predicts how people in a clinical trial will respond to treatment.
The funds will be used to expand the company's workforce and accelerate development of its AI-powered patient engagement platform, Assort OS.
The company will use the funds to scale nationally, broaden partnerships with payers and health systems, and expand into new neurological condition areas.
The company makes upright radiation therapy systems using a fixed beam with slow patient rotation instead of a gantry.
Telehealth company Caregility, hybrid cancer care company Daymark Health and virtual care company AmplifyMD also garnered funding.
The company will use the funds to expand Dreem Health, scale nationwide and advance its FDA-cleared sleep apnea technology.